This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ pediatric high-grade glioma
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of investigational treatment related severe toxicity (Dose-limiting toxicity event)
Timeframe: administration of 8R-70CAR T to 28 days post-infusion
Prevalence of enrolled subjects who receive a qualified immunotherapy investigational product.
Timeframe: Enrollment up to 18 weeks
Maximum tolerated dose (MTD) dose-finding endpoint based on Dose-Limiting-Toxicity (DLT) incidence
Timeframe: administration of 8R-70CAR T to 28 days post-infusion